| Biomarker ID | 1 |
| PMID | 12171882 |
| Year | 2002 |
| Biomarker | p4036+ p4361+ p4413+p4639+p4749+p5666+p28422 (PSA) |
| Biomarker Basis | Expression Based |
| Biomolecule | Protein |
| Source | Tissue |
| Subjects | Humans |
| Regulation | Upregulated in PCa: [p4036; p4361; p4413; p4639; p4749; p28422 (PSA)] Downregulated in PCa: [p5666] |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | Pathways Include:-ID regulation of gene expression,Prostate cancer,Androgen receptor proteolysis and transcription regulation,Androgen receptor signaling, proteolysis, and transcription regulation,Insulin-like growth factor (IGF) activity regulation by insulin-like growth factor binding proteins (IGFBPs) |
| Experiment | Prostate Cancer or Prostatic intraepithelial neoplasia Vs Benign Prostatic Hyperplasia or Normal Prostate |
| Type of Biomarker | Diagnostic |
| Cohort | 8 Normal, 7 BPH (Benign Prostatic Hyperplasia), 9 PIN (prostatic intraepithelial neoplasia), and 7 PCA were selected from 9 patients for this study |
| Senstivity | 93.3% |
| Specificity | 93.8% |
| AUC | NA |
| Accuracy | 93.5% |
| Level Of Significance | NA |
| Method Used | SELDI-TOF MS |
| Clinical | No |
| Remarks | Protein names are given as peaks identified in Mass Spectrometry; p28422 is identified as PSA (Prostate Specific Antigen) |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | KLK3 |